-
ImmuneOnco Achieves Full Enrollment in Phase II Study of IMM01 for CMML
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the successful completion of patient enrollment in its Phase II clinical study (IMM01-02), which investigates the combination of IMM01 with azacitidine for the treatment of naïve chronic myelomonocytic leukemia (CMML). The study has fully enrolled 20 patients, marking a significant milestone in the…
-
Shanghai Bio-Heart Begins RADIUS-HTN Study for Iberis RDN System in France
•
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced the first patient enrollment in the RADIUS-HTN study for its Iberis renal radiofrequency denervation (RDN) system, marking a significant milestone in Bordeaux, France. Objectives and Design of the RADIUS-HTN StudyThe RADIUS-HTN study is designed to assess the performance of…
-
Shenzhen Hepalink’s OncoVent Secures Licensing Deal with Orient EuroPharma for Oregovomab
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has entered into a licensing agreement with Taiwan-based Orient EuroPharma Co., Ltd for the immunotherapy drug oregovomab. The agreement grants Orient exclusive commercialization rights to oregovomab in Taiwan, with additional preemptive rights for exclusive sales, marketing,…
-
Kintor Pharmaceutical Realigns Funds from COVID-19 Studies to Other Pipeline Candidates
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced a strategic change in the allocation of proceeds from previous subscriptions. The company has decided to redirect HKD 509 million (USD 64.8 million), initially intended for the clinical development and commercialization of proxalutamide, pyrilutamide, and AR-PROTAC GT20029, away from clinical studies for…
-
Pfizer Partners with HCRC to Support ‘Healthy China’ Initiative
•
US pharmaceutical giant Pfizer (NYSE: PFE) has announced a strategic partnership agreement with China’s Health China Research Center (HCRC). This long-term collaboration is aimed at supporting the “Healthy China” initiative, with a focus on several key areas including research into equitable access to basic health services, the scientific and standardized…
-
Innovent Biologics Sees 6.7% Revenue Increase in 2022 Amidst R&D Growth and Product Expansion
•
Biopharmaceutical company Innovent Biologics Inc., (HKG: 1801), has reported revenues of RMB 4.55 billion (USD 660.6 million) for 2022, reflecting a 6.7% year-on-year (YOY) increase. Product revenues specifically reached RMB 4.139 billion (USD 600.9 million), up 3.4% YOY. This growth was driven by increased volumes and new product revenues, despite…
-
Astellas Pharma Executive Arrested in China on Spying Allegations
•
A Japanese national and executive at the Chinese division of Tokyo-based Astellas Pharma Inc. (TYO: 4503) has been arrested by China’s state security bureau on suspicion of espionage. The specific details of the alleged charges have not been disclosed to the public. The arrest was initially reported by Japanese media…
-
Shanghai Pharmaceuticals’ SPH4336 Earns Orphan Drug Status for Liposarcoma Treatment
•
Shanghai Pharmaceuticals, a leading pharmaceutical company based in China (HKG: 2607, SHA: 601607), has announced that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its drug candidate, SPH4336. This designation is for the potential treatment of liposarcoma, a rare form of cancer.…
-
Junshi Biosciences and Rxilient Biotech Form JV to Commercialize Tuoyi in Southeast Asia
•
China-based biopharmaceutical company Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a joint venture (JV) with Taiwan-headquartered Rxilient Biotech to develop and commercialize its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab), across Southeast Asia. The agreement covers key territories including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam.…
-
Novartis’ Kisqali Demonstrates Improved iDFS in Phase III NATALEE Study for Early Breast Cancer
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the multi-center, randomized, open-label Phase III NATALEE study has achieved its primary endpoint of invasive disease-free survival (iDFS). The study assessed the efficacy of Kisqali (ribociclib) in combination with endocrine therapy (ET) for hormone receptor-positive/human epidermal growth factor receptor 2 negative…
-
Keymed Biosciences’ CM310 Achieves Primary Endpoints in Phase III Atopic Dermatitis Study
•
China-based Keymed Biosciences Inc., a prominent player in the biopharmaceutical industry (HKG: 2162), has announced that its IL-4Rα monoclonal antibody (mAb) drug candidate, CM310, has successfully reached its primary endpoints in a confirmatory Phase III clinical study for the treatment of moderate to severe atopic dermatitis (AD). Phase III Study…
-
Broncus Medical and Venus Medtech Establish Joint Venture Fund for Digital Medical Equipment
•
Broncus Medical Inc., (HKG: 2216) a leading provider of lung disease precision intervention solutions based in China, has joined forces with Venus Medtech (Hangzhou) Inc., another prominent player in the medical field (HKG: 2500), to announce the establishment of a partnership fund. Each company is contributing RMB 125 million (USD…
-
AstraZeneca Plans Tripled R&D Investment in China, Aims for 15 New Drugs by 2030
•
At the AstraZeneca’s (AZ, NASDAQ: AZN) R&D China Science Day, Yicai Global reported that the UK-based pharmaceutical giant is planning to triple its investment in research and development in China over the coming months. This strategic move aims to increase the number of innovative drugs entering the Chinese market, as…
-
Burning Rock Reports Q4 2022 Revenue Dip but 10.9% Full-Year Growth
•
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its financial results for the fourth quarter of 2022. The company reported Q4 revenues of CNY 142.2 million (USD 20.6 million), marking a 3.5% decrease year-on-year (YOY). However, for the full 12 months, revenues showed a positive trend, increasing by…
-
CDE Grants Priority Review Status to TQB3454, HLX208, and Infigratinib for Cancer Treatments
•
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQB3454, Henlius Bio’s HLX208, and LianBio’s infigratinib are all set to be awarded priority review status as Category 1 chemical drugs. TQB3454: A Promising IDH1 Mutase InhibitorTQB3454 is an in-house developed IDH1 mutase inhibitor intended for the…
-
Brii Biosciences Halts Development of Antibody Cocktail for COVID-19 Treatment
•
Brii Biosciences has announced a strategic decision to end the manufacturing and further development of the amubarvimab/romlusevimab combination treatment regimen for COVID-19. According to the company’s recent 2022 financial report, the antibody cocktail had been commercially available in China from July 2022 following an emergency use authorization (EUA) and had…
-
Berry Genomics Partners with MGI Tech to Advance Cancer Diagnostics and Screening
•
Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary of BGI Group (SHE: 300676), based in China. The collaboration aims to localize and transform comprehensive cancer care by introducing automation platforms for sequencing pipelines across the entire cycle of precise diagnosis and treatment of…
-
PharmaBlock Expands US Presence with New R&D Facility in West Chester
•
PharmaBlock, a leading company based in Nanjing (SHE: 300725), has announced the opening of a new R&D facility in West Chester, Pennsylvania. This strategic move aims to expand the company’s presence in the United States and offer more efficient process R&D services, enabling the fast delivery of clinical-stage GMP projects…
-
CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s Otezla (apremilast) has obtained marketing approval from the National Medical Products Administration (NMPA), signifying that it has passed the generic quality and efficacy consistency evaluation. Apremilast’s Background and Clinical Necessity in ChinaApremilast, an oral small…
-
BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda
•
Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK). This strategic partnership will see the combination of BJ Bio’s pipeline candidate, BJ-001, with MSD’s programmed death-1 (PD-1) inhibitor, Keytruda (pembrolizumab), in a Phase I clinical trial…
